210 related articles for article (PubMed ID: 21484576)
1. Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes.
van Poelje PD; Potter SC; Erion MD
Handb Exp Pharmacol; 2011; (203):279-301. PubMed ID: 21484576
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats.
van Poelje PD; Potter SC; Chandramouli VC; Landau BR; Dang Q; Erion MD
Diabetes; 2006 Jun; 55(6):1747-54. PubMed ID: 16731838
[TBL] [Abstract][Full Text] [Related]
3. CS-917, a fructose 1,6-bisphosphatase inhibitor, improves postprandial hyperglycemia after meal loading in non-obese type 2 diabetic Goto-Kakizaki rats.
Yoshida T; Okuno A; Izumi M; Takahashi K; Hagisawa Y; Ohsumi J; Fujiwara T
Eur J Pharmacol; 2008 Dec; 601(1-3):192-7. PubMed ID: 19014931
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.
Dang Q; Kasibhatla SR; Reddy KR; Jiang T; Reddy MR; Potter SC; Fujitaki JM; van Poelje PD; Huang J; Lipscomb WN; Erion MD
J Am Chem Soc; 2007 Dec; 129(50):15491-502. PubMed ID: 18041834
[TBL] [Abstract][Full Text] [Related]
5. MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.
Erion MD; van Poelje PD; Dang Q; Kasibhatla SR; Potter SC; Reddy MR; Reddy KR; Jiang T; Lipscomb WN
Proc Natl Acad Sci U S A; 2005 May; 102(22):7970-5. PubMed ID: 15911772
[TBL] [Abstract][Full Text] [Related]
6. Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats.
Yoshida T; Okuno A; Tanaka J; Takahashi K; Nakashima R; Kanda S; Ogawa J; Hagisawa Y; Fujiwara T
Eur J Pharmacol; 2009 Nov; 623(1-3):141-7. PubMed ID: 19765581
[TBL] [Abstract][Full Text] [Related]
7. Discovery of fructose-1,6-bisphosphatase inhibitors for the treatment of type 2 diabetes.
van Poelje PD; Dang Q; Erion MD
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):430-7. PubMed ID: 17659484
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.
Dang Q; Liu Y; Cashion DK; Kasibhatla SR; Jiang T; Taplin F; Jacintho JD; Li H; Sun Z; Fan Y; DaRe J; Tian F; Li W; Gibson T; Lemus R; van Poelje PD; Potter SC; Erion MD
J Med Chem; 2011 Jan; 54(1):153-65. PubMed ID: 21126019
[TBL] [Abstract][Full Text] [Related]
9. Managlinat dialanetil, a fructose-1,6-bisphosphatase inhibitor for the treatment of type 2 diabetes.
Wang Y; Tomlinson B
Curr Opin Investig Drugs; 2007 Oct; 8(10):849-58. PubMed ID: 17907062
[TBL] [Abstract][Full Text] [Related]
10. Structure-guided design of AMP mimics that inhibit fructose-1,6-bisphosphatase with high affinity and specificity.
Erion MD; Dang Q; Reddy MR; Kasibhatla SR; Huang J; Lipscomb WN; van Poelje PD
J Am Chem Soc; 2007 Dec; 129(50):15480-90. PubMed ID: 18041833
[TBL] [Abstract][Full Text] [Related]
11. Fructose-1,6-bisphosphatase inhibitors: A new valid approach for management of type 2 diabetes mellitus.
Kaur R; Dahiya L; Kumar M
Eur J Med Chem; 2017 Dec; 141():473-505. PubMed ID: 29055870
[TBL] [Abstract][Full Text] [Related]
12. Fructose-1,6-bisphosphatase inhibitors. 1. Purine phosphonic acids as novel AMP mimics.
Dang Q; Brown BS; Liu Y; Rydzewski RM; Robinson ED; van Poelje PD; Reddy MR; Erion MD
J Med Chem; 2009 May; 52(9):2880-98. PubMed ID: 19348494
[TBL] [Abstract][Full Text] [Related]
13. Increased glucose production in mice overexpressing human fructose-1,6-bisphosphatase in the liver.
Visinoni S; Fam BC; Blair A; Rantzau C; Lamont BJ; Bouwman R; Watt MJ; Proietto J; Favaloro JM; Andrikopoulos S
Am J Physiol Endocrinol Metab; 2008 Nov; 295(5):E1132-41. PubMed ID: 18780768
[TBL] [Abstract][Full Text] [Related]
14. [Recent advance in the discovery of allosteric inhibitors binding to the AMP site of fructose-1,6-bisphosphatase].
Li ZM; Bie JB; Song HR; Xu BL
Yao Xue Xue Bao; 2011 Nov; 46(11):1291-300. PubMed ID: 22260018
[TBL] [Abstract][Full Text] [Related]
15. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
16. New hepatic targets for glycaemic control in diabetes.
Agius L
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):587-605. PubMed ID: 18054737
[TBL] [Abstract][Full Text] [Related]
17. Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.
Dang Q; Kasibhatla SR; Xiao W; Liu Y; Dare J; Taplin F; Reddy KR; Scarlato GR; Gibson T; van Poelje PD; Potter SC; Erion MD
J Med Chem; 2010 Jan; 53(1):441-51. PubMed ID: 20055427
[TBL] [Abstract][Full Text] [Related]
18. Discovery of
Zhou J; Bie J; Wang X; Liu Q; Li R; Chen H; Hu J; Cao H; Ji W; Li Y; Liu S; Shen Z; Xu B
J Med Chem; 2020 Sep; 63(18):10307-10329. PubMed ID: 32820629
[TBL] [Abstract][Full Text] [Related]
19. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
Campbell RK
Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
